Filing Details
- Accession Number:
- 0001104659-24-123807
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-27 19:09:12
- Reporting Period:
- 2024-11-25
- Accepted Time:
- 2024-11-27 19:09:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1377121 | Protagonist Therapeutics Inc | PTGX | Pharmaceutical Preparations (2834) | 980505495 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1763923 | Suneel Gupta | C/O Protagonist Therapeutics, Inc. 7707 Gateway Blvd., Suite 140 Newark CA 94560-1160 | Chief Development Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-25 | 45,000 | $7.38 | 229,611 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-11-25 | 45,000 | $8.02 | 274,611 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-11-25 | 85,000 | $7.80 | 359,611 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-25 | 103,437 | $46.04 | 256,174 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-11-26 | 30,000 | $12.17 | 286,174 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-26 | 19,191 | $45.50 | 266,983 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-11-26 | 450 | $12.17 | 267,433 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-11-25 | 45,000 | $0.00 | 45,000 | $7.38 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-11-25 | 45,000 | $0.00 | 45,000 | $8.02 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-11-25 | 85,000 | $0.00 | 85,000 | $7.80 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-11-26 | 30,000 | $0.00 | 30,000 | $12.17 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-11-26 | 450 | $0.00 | 450 | $12.17 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2029-01-14 | No | 4 | M | Direct | |
| 0 | 2029-02-27 | No | 4 | M | Direct | |
| 0 | 2030-02-27 | No | 4 | M | Direct | |
| 93,750 | 2033-01-15 | No | 4 | M | Direct | |
| 93,300 | 2033-01-15 | No | 4 | M | Direct |
Footnotes
- Includes an aggregate of 1,326 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024.
- Sale to cover the exercise price of the options.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- These stock options are fully vested.
- The stock option vests in 48 equal monthly installments following the date of grant.
Billionaire Hedge Funds
